384,413 results match your criteria Lymphoproliferative Disorders

Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease.

Front Oncol 2022 7;12:854499. Epub 2022 Jun 7.

Department of Rheumatology & Immunology, Wexner Medical Center, The Ohio State University, Columbus, OH, United States.

A complex relationship exists between rheumatic diseases and cancer. This delicate balance between chronic inflammation and malignant cell transformation in hematologic neoplasms has been observed, but is not well defined. Large Granular Lymphocyte (LGL) leukemia is at the intersection of a clonal lymphoproliferative disease, chronic inflammation, and autoimmunity. Read More

View Article and Full-Text PDF

Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Biomolecules 2022 May 27;12(6). Epub 2022 May 27.

Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy.

Unconventional T cells and innate lymphoid cells (ILCs) make up a heterogeneous set of cells that characteristically show prompt responses toward specific antigens. Unconventional T cells recognize non-peptide antigens, which are bound and presented by diverse non-polymorphic antigen-presenting molecules and comprise γδ T cells, MR1-restricted mucosal-associated invariant T cells (MAITs), and natural killer T cells (NKTs). On the other hand, ILCs lack antigen-specific receptors and act as the innate counterpart to the T lymphocytes found in the adaptive immune response. Read More

View Article and Full-Text PDF

Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis.

Curr Oncol 2022 Jun 14;29(6):4245-4259. Epub 2022 Jun 14.

Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.

Chronic lymphocytic leukemia (CLL) is the most common lymphoproliferative disease in adults. Despite durable responses and sustained remission rates to frontline therapy, CLL is still incurable within standard therapy and eventually relapses. Maintenance therapies aim to achieve deep remission. Read More

View Article and Full-Text PDF

Growing Teratoma Syndrome in the Setting of Sarcoidosis: A Case Report and Literature Review.

Curr Oncol 2022 Jun 7;29(6):4148-4154. Epub 2022 Jun 7.

Medical Oncology Department, Blacktown and Westmead Hospitals, Sydney, NSW 2145, Australia.

Growing teratoma syndrome (GTS) is rare and can mimic disease recurrence in patients with a history of immature teratoma. Benign hypermetabolic lymphadenopathy found on staging and surveillance computed tomography (CT) and positron emission tomography (PET) may lead to the presumption of metastatic malignancy. We report a case of a 38 year old with mixed mature and immature teratomas who developed new peritoneal masses after adjuvant chemotherapy despite a normalization of tumor markers. Read More

View Article and Full-Text PDF

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V) Therapy.

Curr Oncol 2022 Jun 6;29(6):4117-4124. Epub 2022 Jun 6.

Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.

Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V), a treatment combination currently being investigated in the setting of refractory multiple myeloma. We also report a unique histopathology and mutational profile that may have important implications for the characterization and prognosis of SMZL. Read More

View Article and Full-Text PDF

[Malignant hypercalcaemia revealing acute lymphoblastic leukemia: case report].

Pan Afr Med J 2022 29;41:257. Epub 2022 Mar 29.

Service d'Hématologie Clinique, Centre Hospitalier Universitaire Mohammed VI Marrakech, Faculté de Médecine et de Pharmacie, Université Cadi Ayyad, Marrakech, Maroc.

Malignant hypercalcaemia is a metabolic emergency. Its association with solid tumors is common, whereas it has been rarely described in patients with malignant hemopathies other than multiple myeloma and T-cell leukemias/T-cell lymphomas associated with lymphotropic virus type I (HTLV-I). We here report the case of a female patient with acute lymphoblastic leukemia revealed by malignant hypercalcaemia and pathological fracture of the humerus. Read More

View Article and Full-Text PDF

m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment.

Front Immunol 2022 6;13:922471. Epub 2022 Jun 6.

Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.

The role of N6-methyladenosine (m6A) modification in tumor microenvironment has rarely been explored in follicular lymphoma (FL). To examine the role of m6A modification in biological behavior, especially the immune landscape of FL, we utilized the Gene Expression Omnibus database to determine the expression signatures of m6A-regulators by unsupervised clustering, and then condense into a risk score, which was validated in an external cohort from the Tianjin Medical University Cancer Institute and Hospital. Finally, 16 m6A-regulators in 351 FL patients were evaluated and two m6A clusters were identified, characterized by differences in prognosis and biological behaviors. Read More

View Article and Full-Text PDF

Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment.

Front Immunol 2022 6;13:915590. Epub 2022 Jun 6.

Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences, Beijing, China.

Measurable residual disease (MRD) positivity before haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an independent prognostic factor in determining outcomes in patients with B-cell acute lymphoblastic leukemia (ALL). In this study, we conducted a parallel comparison of the efficacy and safety in patients with suboptimal MRD response after reinduction who underwent haplo-HSCT after chimeric antigen receptor T-cell (CAR-T) therapy or chemotherapy. Forty B-cell ALL patients who relapsed after first-line chemotherapy and with an MRD ≥0. Read More

View Article and Full-Text PDF

High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up.

Sci Rep 2022 Jun 22;12(1):10551. Epub 2022 Jun 22.

Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, 5 WK Roentgen Str, 02-781, Warsaw, Poland.

Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85-95% of patients. Treatment regimens frequently used include RCHOP ± radiotherapy, DAEPOCH-R, or occasionally more intensive protocols. Here we present results of treatment of 124 patients with PMBL over a period between 2004 and 2017 with the use of a protocol designed for aggressive B-cell lymphoma GMALL/B-ALL/NHL2002 including 6 cycles of alternating immunochemotherapy with intermediate-dose methotrexate in each cycle, and reduced total doxorubicin dose (100 mg/m for whole treatment). Read More

View Article and Full-Text PDF

Hypogammaglobulinaemia and B cell lymphopaenia in Barth syndrome.

BMJ Case Rep 2022 Jun 22;15(6). Epub 2022 Jun 22.

Pediatrics, Umm Al-Qura University College of Medicine, Makkah, Saudi Arabia

Barth syndrome (BTHS) is an X linked recessive disorder caused by a mutation in the tafazzin (TAZ) gene classically associated with the triad of neutropaenia and cardiac and skeletal myopathies. Here we present a case of BTHS in a 2-month-old male patient found to have a novel variant of the TAZ gene (hemizygous c.639G>A) leading to early termination of the tafazzin protein (p. Read More

View Article and Full-Text PDF

Secondary B-cell acute lymphoblastic leukaemia in a patient with multiple myeloma.

BMJ Case Rep 2022 Jun 22;15(6). Epub 2022 Jun 22.

Hematology and Oncology, VA West Los Angeles Medical Center, Los Angeles, California, USA.

Although patients with multiple myeloma (MM) have improved survival with current therapies, there remains a long-term risk of treatment-associated second primary malignancies. We present a case of a patient with IgG kappa MM undergoing treatment for relapsed disease who was noted to have progressive pancytopenia. For his MM, he had previously undergone autologous stem cell transplant with high-dose melphalan and had received immunomodulatory (IMiD) agents in induction, maintenance and relapse regimens. Read More

View Article and Full-Text PDF

Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma.

BMJ Case Rep 2022 Jun 22;15(6). Epub 2022 Jun 22.

Hematology and Oncology, The University of Texas McGovern Medical School, Houston, Texas, USA.

Mantle cell lymphoma (MCL) is an incurable B cell non-Hodgkin's lymphoma with a variable clinical course. Central nervous system (CNS) involvement is a rare and dreaded complication in MCL. We report a case of leptomeningeal relapse of MCL that was successfully treated with a single-agent Bruton's tyrosine kinase inhibitor. Read More

View Article and Full-Text PDF

What cardiologists should know about cardiac sarcoidosis in 2022?

Curr Opin Cardiol 2022 Jul;37(4):380-387

Department of Cardiology, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Quebec City, Quebec, Canada.

Purpose Of Review: Cardiac sarcoidosis (CS) is a potentially fatal condition when unrecognized or not treated adequately. The purpose of this review is to provide new strategies to increase clinical recognition of CS and to present an updated overview of the immunosuppressive treatments using most recent data published in the last 18 months.

Recent Findings: CS is an increasingly recognized pathology, and its diagnostic is made 20 times more often in the last two decades. Read More

View Article and Full-Text PDF

Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

N Engl J Med 2022 06;386(25):2399-2411

From Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome.

View Article and Full-Text PDF

Evolving third-line treatment options for follicular lymphoma.

John M Burke

Clin Adv Hematol Oncol 2022 Jun;20(6):394-396

US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, Colorado.

View Article and Full-Text PDF

Follicular lymphoma grade 3: a comprehensive review.

Clin Adv Hematol Oncol 2022 Jun;20(6):384-390

King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Follicular lymphoma (FL) is a heterogeneous entity with disparate outcomes based on clinical and pathologic characteristics. An increasingly detailed understanding of high-grade FL (grade 3) has led to the identification of separate categories of FL3A and FL3B. Recently, genomic studies have made much progress in delineating the genetic differences between FL3A and FL3B. Read More

View Article and Full-Text PDF

The use of chimeric antigen T-cell therapy in chronic lymphocytic leukemia.

Tanya Siddiqi

Clin Adv Hematol Oncol 2022 Jun;20(6):366-368

Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California.

View Article and Full-Text PDF

Non-Hodgkin-Lymphom: HIV erhöht Risiko drastisch.

MMW Fortschr Med 2022 Jun;164(Suppl 2):15

Springer Medizin Verlag GmbH, Aschauer Str. 30, 81549, München, Germany.

View Article and Full-Text PDF

Hodgkin Lymphoma after Disseminated Mycobacterium genavense Infection, Germany.

Emerg Infect Dis 2022 Jul;28(7):1506-1509

Mycobacterium genavense infection, a rare nontuberculous mycobacteria infection, occurs in heavily immunocompromised patients (i.e., those with advanced HIV disease, genetic disorders, or acquired immunologic disorders and those undergoing immunosuppressive therapy). Read More

View Article and Full-Text PDF

The dense-core plaques of Alzheimer's disease are granulomas.

J Exp Med 2022 Aug 22;219(8). Epub 2022 Jun 22.

Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA.

Dense-core plaques, whose centers contain highly polymerized and compacted aggregates of amyloid β peptides, are one of the two defining histopathological features of Alzheimer's disease. Recent findings indicate that these plaques do not form spontaneously but are instead constructed by microglia, the tissue macrophages of the central nervous system. We discuss cellular, structural, functional, and gene expression criteria by which the microglial assembly of dense-core plaques in the Alzheimer's brain parallels the construction of granulomas by macrophages in other settings. Read More

View Article and Full-Text PDF

Haploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission.

Chin Med J (Engl) 2022 Apr 20;135(8):940-949. Epub 2022 Apr 20.

Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing 100044, China.

Background: The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with high-risk (HR) T-cell acute lymphoblastic leukemia (T-ALL) in first complete remission (CR1) is still under evaluation. Moreover, relapse is the main factor affecting survival. This study aimed to explore the effect of allo-HSCT (especially haploidentical HSCT [haplo-HSCT]) on improving survival and reducing relapse for HR childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in order to identify who could benefit from HSCT. Read More

View Article and Full-Text PDF

Overexpression of c-Myc-dependent heterogeneous nuclear ribonucleoprotein A1 promotes proliferation and inhibits apoptosis in NOTCH1-mutated chronic lymphocytic leukemia cells.

Chin Med J (Engl) 2022 Apr 20;135(8):920-929. Epub 2022 Apr 20.

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China.

Background: NOTCH1 mutation is an essential molecular biologic aberration in chronic lymphocytic leukemia (CLL). CLL patients with NOTCH1 mutation have shown an unfavorable survival and a poor response to chemoimmunotherapy. This study aims to present the mechanisms of adverse prognosis caused by NOTCH1 mutation from the perspective of the splicing factor heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1). Read More

View Article and Full-Text PDF

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity.

Sci Rep 2022 Jun 21;12(1):10488. Epub 2022 Jun 21.

Institute of Biology and Medicine, College of Life and Health Sciences, Wuhan University of Science and Technology, Hubei, 430081, China.

CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). However, even second- generation anti-CD30 CAR T-cells with CD28 (28z) costimulatory domains failed to achieve the desired rate of complete responses. In the present study, we developed second-generation (CD28z) and third-generation (CD28BBz) CAR T-cells targeting CD30 and investigated their efficacy in vitro and in vivo. Read More

View Article and Full-Text PDF

Utility of targeted next generation sequencing for inborn errors of immunity at a tertiary care centre in North India.

Sci Rep 2022 Jun 21;12(1):10416. Epub 2022 Jun 21.

Allergy Immunology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.

Inborn errors of immunity (IEI) are a heterogeneous group of monogenic disorders that include primary immunodeficiency's and other disorders affecting different aspects of the immune system. Next-Generation Sequencing (NGS) is an essential tool to diagnose IEI. We report our 3-year experience in setting up facilities for NGS for diagnosis of IEI in Chandigarh, North India. Read More

View Article and Full-Text PDF

Primary Central Nervous System Burkitt Lymphoma, Presenting with Long-Term Fluctuating Level of Consciousness: A Case Report and Literature Review on Challenges in Diagnosis and Management.

Am J Case Rep 2022 Jun 21;23:e936401. Epub 2022 Jun 21.

Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

BACKGROUND Burkitt lymphoma (BL) is an aggressive subtype of B-cell non-Hodgkin lymphoma (NHL) rarely affecting the central nervous system (CNS) as a primary disease. Over the past years, only a few cases of primary CNS Burkitt lymphoma were reported. There is a challenge in early recognition and diagnosis of this type of brain lymphoma. Read More

View Article and Full-Text PDF

Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.

BMC Cancer 2022 Jun 20;22(1):678. Epub 2022 Jun 20.

Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden.

Background: The therapeutic IgG1 anti-CD20 antibody, rituximab (RTX), has greatly improved prognosis of many B-cell malignancies. Despite its success, resistance has been reported and detailed knowledge of RTX mechanisms are lacking. Complement-dependent cytotoxicity (CDC) is one important mode of action of RTX. Read More

View Article and Full-Text PDF

[Interpretation of Chinese expert consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with lymphoma (2022)].

N Wei Z Wang

Zhonghua Yi Xue Za Zhi 2022 Jun;102(24):1779-1781

Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

Chinese expert consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis (HLH) associated with lymphoma was revised on the basis of evidence-based medical evidence in combination with domestic and international research progress. It added the classification of "according to the difference in the causes of HLH". For the first time, the revised version included the classification of lymphoma-associated HLH induced by immunotherapy. Read More

View Article and Full-Text PDF

Complexities in diagnosing and treating endophthalmitis in the post stem cell transplant setting.

BMJ Case Rep 2022 Jun 20;15(6). Epub 2022 Jun 20.

Clinical Microbiology, HSE, Dublin, Ireland.

Endophthalmitis is a rare but sight-threatening manifestation of systemic infection. Immunosuppression is a well-recognised risk factor for development of endophthalmitis. Determining the aetiology can be complex, particularly in the context of immunosuppression, we present the diagnostic and treatment dilemmas associated with a patient who complains of blurred vision 2 weeks following an allogeneic stem cell transplant for refractory Hodgkin's disease. Read More

View Article and Full-Text PDF

Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused".

Oncology (Williston Park) 2022 Jun;36(6):366-375

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Approximately 30% to 40% of patients will develop relapsed/refractory (R/R) DLBCL, leading to significant morbidity and mortality. Salvage chemoimmunotherapy followed by high-dose chemotherapy and autologous stem cell rescue (HDT-ASCR) is the standard of care for chemosensitive and transplant-eligible R/R DLBCL. Read More

View Article and Full-Text PDF